Browse CEBPA

Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus ; SUBCELLULAR LOCATION: Isoform 4: Nucleus, nucleolus
Domain PF07716 Basic region leucine zipper
Function

Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity). ; FUNCTION: Isoform 3: Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation (PubMed:14660596). ; FUNCTION: Isoform 4: Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation.

> Gene Ontology
 
Biological Process GO:0000050 urea cycle
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001701 in utero embryonic development
GO:0001889 liver development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001933 negative regulation of protein phosphorylation
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0006066 alcohol metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006359 regulation of transcription from RNA polymerase III promoter
GO:0006383 transcription from RNA polymerase III promoter
GO:0006469 negative regulation of protein kinase activity
GO:0007219 Notch signaling pathway
GO:0007423 sensory organ development
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0010498 proteasomal protein catabolic process
GO:0016125 sterol metabolic process
GO:0019627 urea metabolic process
GO:0021700 developmental maturation
GO:0030099 myeloid cell differentiation
GO:0030225 macrophage differentiation
GO:0030278 regulation of ossification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030851 granulocyte differentiation
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0033500 carbohydrate homeostasis
GO:0033673 negative regulation of kinase activity
GO:0042176 regulation of protein catabolic process
GO:0042326 negative regulation of phosphorylation
GO:0042593 glucose homeostasis
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043583 ear development
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045732 positive regulation of protein catabolic process
GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045778 positive regulation of ossification
GO:0045786 negative regulation of cell cycle
GO:0045862 positive regulation of proteolysis
GO:0045945 positive regulation of transcription from RNA polymerase III promoter
GO:0048469 cell maturation
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048732 gland development
GO:0048839 inner ear development
GO:0050872 white fat cell differentiation
GO:0050873 brown fat cell differentiation
GO:0051348 negative regulation of transferase activity
GO:0055088 lipid homeostasis
GO:0060541 respiratory system development
GO:0061008 hepaticobiliary system development
GO:0061136 regulation of proteasomal protein catabolic process
GO:0061458 reproductive system development
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071285 cellular response to lithium ion
GO:0071407 cellular response to organic cyclic compound
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0071941 nitrogen cycle metabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1902652 secondary alcohol metabolic process
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904030 negative regulation of cyclin-dependent protein kinase activity
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0003713 transcription coactivator activity
GO:0008134 transcription factor binding
Cellular Component GO:0005667 transcription factor complex
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEBPA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CEBPA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19805226LeukemiaInhibit immunity (T cell function)These T cells also reveal a unique molecular signature, including a strong expression of C/EBPalpha normally expressed in myeloid-lineage cells, with diminished c-Myc and cyclin D1. Transduction of Cebpa in regular CD4(+) T cells inhibited the TCR-mediated proliferation with c-Myc and cyclin D1 repression and caused a striking activation of Spp1 encoding osteopontin along with concomitant repression of T cell lymphokine genes. The results suggest that global T cell immunodepression in senescence and leukemia is attributable to the increase in PD-1(+) MP CD4(+) T cells expressing C/EBPalpha
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEBPA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEBPA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4410.446
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4660.796
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.1110.389
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2420.755
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4880.744
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1720.542
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5540.313
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1790.336
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2380.871
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2570.604
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6580.353
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1070.568
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEBPA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEBPA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEBPA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEBPA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEBPA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEBPA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEBPA
NameCCAAT/enhancer binding protein (C/EBP), alpha
Aliases C/EBP-alpha; CEBP; C/EBP alpha; CCAAT/enhancer-binding protein alpha
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEBPA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.